Latest Regulatory Progress News

Buru Energy has enhanced the Rafael Gas Project’s mid-case value by over 45% through new engineering insights, while securing A$5.3 million to advance development. The company delayed appraisal drilling to 2027 to optimise funding and project design, and navigates a leadership change with CEO Thomas Nador stepping down.

Invictus Energy has raised $10 million in a placement to fund the drilling of the Musuma-1 exploration well, targeting a substantial gas and condensate resource in Zimbabwe’s Cabora Bassa Basin. The well, planned for H2 2026, aims to build on the Mukuyu discovery and accelerate commercial development.

Anson Resources has lodged an updated Small Mining Operations notice for its 10,000tpa Green River lithium carbonate plant in Utah, marking the last significant regulatory hurdle before construction. The revised plant layout, backed by a near-complete Pre-feasibility Study, leverages existing infrastructure and private land ownership to enhance project bankability.

Lumos Diagnostics has secured a key FDA 510(k) clearance with CLIA waiver for its FebriDx rapid test, unlocking a US$1 billion-plus market opportunity and triggering milestone payments exceeding US$6 million. The company reported a 37% revenue jump in Q3 FY26, supported by a A$20 million placement and ongoing clinical and development projects.

Patrys has raised A$3.2 million through a share placement to fund its injectable quetiapine program’s Phase 1A clinical trial and FDA pre-IND preparations.

BMC Minerals has kicked off its 2026 drilling campaign at the Kudz Ze Kayah Project with a standout massive sulphide intercept at the Krakatoa Zone, pointing to potential extensions beyond current reserves and a longer mine life.

29Metals Limited (ASX:29M) swung to a $24 million net profit in 2025, powered by steady copper output at Golden Grove despite seismic disruptions, cost efficiencies, and key progress on growth projects including Gossan Valley and Capricorn Copper restart.

Memphasys Limited has marked a milestone quarter with revenue surpassing A$100,000, driven by repeat orders and multi-year contracts, signalling its transition to a commercially focused biotech business.

Audalia Resources is set to raise $450,000 through a share placement aimed at funding critical mining design and permit work for its Medcalf Project, supporting its path toward development.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

Telix Pharmaceuticals and Regeneron have entered a strategic collaboration to co-develop next-generation radiopharmaceutical therapies, with Telix receiving a $40 million upfront payment and potential milestones exceeding $2 billion.

Telix Pharmaceuticals has announced FDA acceptance of its resubmitted NDA for TLX101-Px (Pixclara®), a PET imaging agent for glioma, setting a PDUFA goal date of September 11, 2026. The agent addresses a significant unmet need in distinguishing recurrent glioma from treatment effects.